Betaspan Depot suspension for injection ampoules 1 ml 5 pcs
Condition: New product
999 Items
More info
Active ingredients
Release form
Composition
Suspension for injection 1 ml
active substances:
- betamethasone dipropionate 6.43 mg (equivalent to 5 mg of betamethasone)
- betamethasone sodium phosphate 2.63 mg (equivalent to 2 mg betamethasone)
- Excipients: methyl parahydroxybenzoate (E218) - 1.3 mg; propyl parahydroxybenzoate (E216) - 0.2 mg; benzyl alcohol - 9 mg; sodium chloride - 5.5 mg; sodium phosphate - 0.6 mg; disodium edetate dihydrate - 0.1 mg; carmellose sodium - 5.2 mg; polysorbate 80 - 0.5 mg; macrogol 4000 - 25 mg; water for injection - up to 1 ml
Pharmacological effect
Pharmacological action - anti-inflammatory, antiallergic, immunosuppressive, glucocorticoid.
Dosage and administration
V / m, intraarticular, periarticular, intrabursal, iv, interstitial and intrafocal introduction.
The insignificant size of betamethasone dipropionate crystals allows the use of needles of small diameter (up to 26 gauge) for intravenous injection and injection directly into the lesion.
It is impossible to enter in / in and p / to.
Strict adherence to the rules of asepsis is mandatory when using the drug.
Shake the syringe before administering the drug.
The dosage regimen and method of administration are set individually, depending on the indications, the severity of the disease and the patient's response.
With systemic therapy, the initial dose of Betaspan® Depot in most cases is 1–2 ml. The introduction is repeated as necessary, depending on the condition of the patient.
V / m introduction
V / m injection of the drug Betaspan Depot should be carried out deep into the muscle, while choosing large muscles and avoiding contact with other tissues (to prevent tissue atrophy).
In severe conditions requiring emergency measures, the initial dose is 2 ml of the drug.
In various dermatological diseases, as a rule, 1 ml of the preparation is sufficient.
In diseases of the respiratory system, the onset of action of the drug occurs within a few hours after the i / m injection.
In case of bronchial asthma, hay fever, allergic bronchitis and allergic rhinitis, a significant improvement in condition is achieved after the administration of 1–2 ml of the drug.
In acute and chronic bursitis, the initial dose for intramuscular administration is 1-2 ml of the drug.If necessary, carry out several repeated injections.
If a satisfactory clinical response does not occur after a certain period of time, the drug should be withdrawn and another therapy prescribed.
Local introduction
With local administration, the simultaneous use of a local anesthetic preparation is necessary only in rare cases. If it is desired, then use 1 or 2% solutions of procain hydrochloride or lidocaine, which do not contain methyl paraben, propyl paraben, phenol and other similar substances. In this case, mixing is carried out in a syringe, first dialing the required dose of Betaspan® Depot into a syringe from a vial. Then, in the same syringe, take the required amount of local anesthetic from the ampoule and shake it for a short period of time.
In acute bursitis (subdeltoid, subscapularis, elbow, and pre-knee), the introduction of 1–2 ml of the drug in the synovial bag relieves pain and restores mobility of the joint for several hours. After arresting the exacerbation of chronic bursitis, lower doses of the drug are used.
In acute tenosynovitis, tendinitis and perienendinitis one injection of the drug improves the patient's condition; in chronic injections, repeat depending on the response of the patient. The introduction of the drug directly into the tendon should be avoided.
Intra-articular administration of the drug in a dose of 0.5-2 ml relieves pain, limiting the mobility of the joints in rheumatoid arthritis and osteoarthrosis within 2-4 hours after administration. The duration of the therapeutic effect varies considerably and can be 4 weeks or more.
Recommended doses of the drug when administered in large joints range from 1 to 2 ml; in average - 0.5–1 ml; in small - 0.25–0.5 ml.
In some dermatological diseases it is effective to / to administer the drug directly into the lesion, the dose is 0.2 ml / cm2. The lesion is evenly cut off using a tuberculin syringe and needle with a diameter of about 0.9 mm. The total amount of the administered drug in all areas should not exceed 1 ml for 1 week. A tuberculin syringe with a 26 gauge needle is recommended for insertion into the lesion.
Recommended single doses of the drug (with an interval of 1 week between injections) in case of bursitis: with a mole callus - 0.25–0.5 ml (2 injections are usually effective), with a spur - 0.5 ml, with limited mobility of the big toe - 0.5 ml, with synovial cysts - 0.25–0.5 ml, with tendosynovitis - 0.5 ml, with acute gouty arthritis - 0.5–1 ml. For most injections, a tuberculin syringe with a 25 gauge needle is suitable.
After reaching the therapeutic effect, the maintenance dose is selected by gradually reducing the dose of Betaspan® Depo, administered at appropriate intervals. The reduction is continued until the minimum effective dose is reached.
If a stress situation (not related to the disease) arises or is threatened, it may be necessary to increase the dose of the drug. The abolition of the drug after long-term therapy is carried out by gradually reducing the dose. The patient’s condition is monitored for at least one year after the end of long-term therapy or high-dose administration.
Storage conditions
Suspension for injection, 7 mg / ml. In glass ampoules with a fracture ring (or a break point), 1 ml. Self-adhesive labels are attached to the ampoules. 1 or 5 amp. in a polymer film blister. 1 bl. with ampoules in a pack of cardboard.
In the dark place at a temperature of no higher than 25 ° C (not freezing).
Keep out of the reach of children.